GSK's Setback and Final Trading Insights

This chapter examines the repercussions of the FDA advisory committee's unfavorable recommendation for GSK's multiple myeloma drug, Blenrep, which led to a 6 percent drop in shares. The hosts also provide insights on final trades and stock strategies in response to the news.